Two Sigma Investments, LP Revance Therapeutics, Inc. Transaction History

Two Sigma Investments, LP

$41.6 Billion
Q4 2024

A detailed history of Two Sigma Investments, LP transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Investments, LP holds 170,136 shares of RVNC stock, worth $437,249. This represents 0.0% of its overall portfolio holdings.

Number of Shares

170,136

Previous 156,597 8.65%

Holding current value

$437,249

Previous $402,000 8.71%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	N/A	13,539 Added 8.65%	170,136 $437,000
Q3 2024 Nov 14, 2024	SELL	$2.57 - $2.57 $1.23 Million - $1.23 Million	-477,306 Reduced 75.3%	156,597 $402,000
Q2 2024 Aug 14, 2024	BUY	$2.34 - $4.73 $881,024 - $1.78 Million	376,506 Added 146.27%	633,903 $1.63 Million
Q1 2024 May 15, 2024	BUY	$4.65 - $9.31 $1.2 Million - $2.4 Million	257,397 New	257,397 $1.27 Million
Q2 2023 Aug 14, 2023	SELL	$24.7 - $37.61 $13.8 Million - $21 Million	-557,499 Reduced 40.56%	816,839 $20.7 Million
Q1 2023 May 15, 2023	BUY	$18.36 - $35.27 $425,658 - $817,699	23,184 Added 1.72%	1,374,338 $44.3 Million
Q4 2022 Feb 14, 2023	BUY	$18.32 - $30.66 $4.2 Million - $7.03 Million	229,331 Added 20.44%	1,351,154 $24.9 Million
Q3 2022 Nov 14, 2022	BUY	$14.33 - $28.47 $11.1 Million - $22.1 Million	777,135 Added 225.46%	1,121,823 $30.3 Million
Q2 2022 Aug 15, 2022	BUY	$11.52 - $20.4 $2.71 Million - $4.8 Million	235,292 Added 215.08%	344,688 $4.76 Million
Q1 2022 May 16, 2022	BUY	$12.36 - $20.31 $254,492 - $418,182	20,590 Added 23.19%	109,396 $2.13 Million
Q4 2021 Feb 14, 2022	BUY	$12.46 - $27.87 $1.11 Million - $2.48 Million	88,806 New	88,806 $1.45 Million
Q4 2020 Feb 16, 2021	SELL	$23.41 - $28.34 $766,022 - $927,341	-32,722 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$23.23 - $34.3 $455,609 - $672,725	19,613 Added 149.61%	32,722 $823,000
Q2 2020 Aug 14, 2020	SELL	$12.6 - $26.55 $1.45 Million - $3.05 Million	-114,858 Reduced 89.76%	13,109 $320,000
Q1 2020 May 15, 2020	BUY	$12.46 - $27.81 $947,769 - $2.12 Million	76,065 Added 146.56%	127,967 $1.89 Million
Q4 2019 Feb 14, 2020	BUY	$11.66 - $20.15 $605,177 - $1.05 Million	51,902 New	51,902 $842,000
Q3 2019 Nov 14, 2019	SELL	$10.22 - $14.5 $370,393 - $525,509	-36,242 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$10.67 - $15.49 $861,815 - $1.25 Million	-80,770 Reduced 69.03%	36,242 $470,000
Q1 2019 May 15, 2019	BUY	$15.4 - $20.39 $1.8 Million - $2.39 Million	117,012 New	117,012 $1.84 Million
Q4 2018 Feb 14, 2019	SELL	$18.06 - $24.96 $705,044 - $974,413	-39,039 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$23.55 - $30.1 $2.51 Million - $3.21 Million	-106,638 Reduced 73.2%	39,039 $970,000
Q2 2018 Aug 14, 2018	BUY	$27.45 - $33.35 $2.69 Million - $3.26 Million	97,822 Added 204.41%	145,677 $4 Million
Q1 2018 May 15, 2018	SELL	$29.15 - $37.4 $1.06 Million - $1.36 Million	-36,287 Reduced 43.13%	47,855 $1.47 Million
Q4 2017 Feb 14, 2018	BUY	$24.55 - $36.3 $2.07 Million - $3.05 Million	84,142	84,142 $3.01 Million

Others Institutions Holding RVNC

# of Institutions

208

Shares Held

80.9M

Call Options Held

2.26M

Put Options Held

5.48M

View Full List

About Revance Therapeutics, Inc.

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

More about RVNC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.

Account

Two Sigma Investments, LP Revance Therapeutics, Inc. Transaction History